We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of Kewaunee Scientific Corporation (KEQU - Free Report) have declined 19.7% since reporting first-quarter fiscal 2026 results. This compares with the S&P 500 index’s 0.4% rise over the same period. Over the past month, the stock has fallen 23.8%, while the S&P 500 has advanced 1.9%. The performance highlights a sharp underperformance relative to the broader market despite a set of results that, on balance, showed strong top and bottom-line growth.
Earnings & Revenue Performance
The company reported first-quarter fiscal 2026 sales of $71.1 million, a 46.9% increase from $48.4 million in the prior-year quarter. Net earnings rose 41.1% to $3.1 million from $2.2 million a year ago. Diluted earnings per share grew 40.5% to $1.04 from 74 cents in the same quarter last year. EBITDA nearly doubled to $6.3 million from $3.3 million in the prior-year period. This robust performance was underpinned by growth across both domestic and international segments, as well as contributions from the recently acquired Nu Aire business.
Kewaunee Scientific Corporation Price, Consensus and EPS Surprise
The company’s order backlog stood at $205 million as of July 31, 2025, up from $159.4 million a year earlier, though slightly down from $214.6 million at the end of April 2025.
Domestic sales soared 53% to $54.4 million, while international sales advanced 30.2% to $16.8 million. The domestic segment delivered net earnings of $4.7 million compared with $2.9 million a year ago, while international earnings improved to $0.6 million from $0.5 million. Segment EBITDA also grew strongly — $7.6 million for domestic and $1.1 million for international, reflecting improved productivity and higher billings.
Working capital rose to $66.7 million from $56 million a year earlier, while total cash on hand increased to $20.4 million at quarter-end from $17.2 million in April 2025. Debt metrics showed improvement. Short-term debt declined to $4.3 million from $4.8 million in April, and long-term debt eased to $60.3 million from $60.7 million. The debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1 three months earlier.
Management Commentary
CEO Thomas D. Hull III acknowledged that the strong quarterly results were achieved against a backdrop of challenging market conditions, including shifting government policies, evolving tariffs and geopolitical uncertainties. He cautioned that the company expects uneven quarterly performance through fiscal 2026 due to volatility in project delivery timelines, which is characteristic of construction-related manufacturing.
However, management reiterated its commitment to growth, both organically and through acquisitions, supported by investments in people, processes and technology.
Factors Influencing the Headline Numbers
The incorporation of Nu Aire’s results was a significant factor in boosting domestic sales and earnings. The company also benefited from steady manufacturing volumes, cost management actions and reduced site delays internationally compared with the prior year.
Conversely, the corporate segment continued to weigh on consolidated results, with a pre-tax net loss of $3.1 million compared with a $2-million loss a year ago. Corporate segment EBITDA was negative $2.3 million, reflecting higher compliance costs and ongoing investments in corporate infrastructure.
View
Management refrained from providing specific financial guidance but indicated that it expects unadjusted EBITDA for fiscal 2026 to surpass that of fiscal 2025. While acknowledging that strategic investments will place pressure on near-term earnings, leadership emphasized confidence in long-term growth prospects, citing anticipated leverage from these investments.
Other Developments
The most notable development in the quarter was the integration of Nu Aire, Inc., which was acquired on Nov. 1, 2024. Nu Aire’s contribution was visible in domestic sales and earnings growth. Professional and other fees tied to the integration amounted to $224,000 during the quarter. Nu Aire, a Minnesota-based manufacturer of biological safety cabinets, incubators and ultralow freezers, expands Kewaunee’s presence in critical laboratory and healthcare markets.
In summary, Kewaunee Scientific delivered a quarter of strong growth in revenues and profitability, supported by robust domestic demand, improved international operations, and contributions from the Nu Aire acquisition. However, despite these positive results, the stock has significantly underperformed the broader market in recent weeks, reflecting investor concerns about uneven project delivery timelines, rising corporate costs, and macroeconomic uncertainties.
While management projects stronger EBITDA for the year, market sentiment remains cautious, underscoring the challenges the company faces in translating its operational momentum into a sustained stock performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Kewaunee Scientific Q1 Earnings Rise Y/Y, Stock Slides 19%
Shares of Kewaunee Scientific Corporation (KEQU - Free Report) have declined 19.7% since reporting first-quarter fiscal 2026 results. This compares with the S&P 500 index’s 0.4% rise over the same period. Over the past month, the stock has fallen 23.8%, while the S&P 500 has advanced 1.9%. The performance highlights a sharp underperformance relative to the broader market despite a set of results that, on balance, showed strong top and bottom-line growth.
Earnings & Revenue Performance
The company reported first-quarter fiscal 2026 sales of $71.1 million, a 46.9% increase from $48.4 million in the prior-year quarter. Net earnings rose 41.1% to $3.1 million from $2.2 million a year ago. Diluted earnings per share grew 40.5% to $1.04 from 74 cents in the same quarter last year. EBITDA nearly doubled to $6.3 million from $3.3 million in the prior-year period. This robust performance was underpinned by growth across both domestic and international segments, as well as contributions from the recently acquired Nu Aire business.
Kewaunee Scientific Corporation Price, Consensus and EPS Surprise
Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote
Other Key Business Metrics
The company’s order backlog stood at $205 million as of July 31, 2025, up from $159.4 million a year earlier, though slightly down from $214.6 million at the end of April 2025.
Domestic sales soared 53% to $54.4 million, while international sales advanced 30.2% to $16.8 million. The domestic segment delivered net earnings of $4.7 million compared with $2.9 million a year ago, while international earnings improved to $0.6 million from $0.5 million. Segment EBITDA also grew strongly — $7.6 million for domestic and $1.1 million for international, reflecting improved productivity and higher billings.
Working capital rose to $66.7 million from $56 million a year earlier, while total cash on hand increased to $20.4 million at quarter-end from $17.2 million in April 2025. Debt metrics showed improvement. Short-term debt declined to $4.3 million from $4.8 million in April, and long-term debt eased to $60.3 million from $60.7 million. The debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1 three months earlier.
Management Commentary
CEO Thomas D. Hull III acknowledged that the strong quarterly results were achieved against a backdrop of challenging market conditions, including shifting government policies, evolving tariffs and geopolitical uncertainties. He cautioned that the company expects uneven quarterly performance through fiscal 2026 due to volatility in project delivery timelines, which is characteristic of construction-related manufacturing.
However, management reiterated its commitment to growth, both organically and through acquisitions, supported by investments in people, processes and technology.
Factors Influencing the Headline Numbers
The incorporation of Nu Aire’s results was a significant factor in boosting domestic sales and earnings. The company also benefited from steady manufacturing volumes, cost management actions and reduced site delays internationally compared with the prior year.
Conversely, the corporate segment continued to weigh on consolidated results, with a pre-tax net loss of $3.1 million compared with a $2-million loss a year ago. Corporate segment EBITDA was negative $2.3 million, reflecting higher compliance costs and ongoing investments in corporate infrastructure.
View
Management refrained from providing specific financial guidance but indicated that it expects unadjusted EBITDA for fiscal 2026 to surpass that of fiscal 2025. While acknowledging that strategic investments will place pressure on near-term earnings, leadership emphasized confidence in long-term growth prospects, citing anticipated leverage from these investments.
Other Developments
The most notable development in the quarter was the integration of Nu Aire, Inc., which was acquired on Nov. 1, 2024. Nu Aire’s contribution was visible in domestic sales and earnings growth. Professional and other fees tied to the integration amounted to $224,000 during the quarter. Nu Aire, a Minnesota-based manufacturer of biological safety cabinets, incubators and ultralow freezers, expands Kewaunee’s presence in critical laboratory and healthcare markets.
In summary, Kewaunee Scientific delivered a quarter of strong growth in revenues and profitability, supported by robust domestic demand, improved international operations, and contributions from the Nu Aire acquisition. However, despite these positive results, the stock has significantly underperformed the broader market in recent weeks, reflecting investor concerns about uneven project delivery timelines, rising corporate costs, and macroeconomic uncertainties.
While management projects stronger EBITDA for the year, market sentiment remains cautious, underscoring the challenges the company faces in translating its operational momentum into a sustained stock performance.